BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology & Metabolism 2013;24:238-46. [DOI: 10.1016/j.tem.2012.11.007] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Hernández-Ramírez LC, Trivellin G, Stratakis CA. Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease. Mol Cell Endocrinol 2018;463:72-86. [PMID: 28822849 DOI: 10.1016/j.mce.2017.08.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
2 Alexandraki KI, Papadimitriou E, Mavroeidi V, Kyriakopoulos G, Xydakis A, Papaioannou TG, Kolomodi D, Kaltsas GA, Grossman AB. Role of Receptor Profiling for Personalized Therapy in a Patient with a Growth Hormone-Secreting Macroadenoma Resistant to First-Generation Somatostatin Analogues. J Pers Med 2019;9:E48. [PMID: 31731613 DOI: 10.3390/jpm9040048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hong GK, Payne SC, Jane JA Jr. Anatomy, Physiology, and Laboratory Evaluation of the Pituitary Gland. Otolaryngol Clin North Am 2016;49:21-32. [PMID: 26614827 DOI: 10.1016/j.otc.2015.09.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
4 Coopmans EC, Korevaar TIM, van Meyel SWF, Daly AF, Chanson P, Brue T, Delemer B, Hána V, Colao A, Carvalho D, Jaffrain-Rea ML, Stalla GK, Fajardo-Montañana C, Beckers A, van der Lely AJ, Petrossians P, Neggers SJCMM. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. J Clin Endocrinol Metab 2020;105:dgaa387. [PMID: 32589751 DOI: 10.1210/clinem/dgaa387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
5 Ozkaya HM, Comunoglu N, Sayitoglu M, Keskin FE, Firtina S, Khodzhaev K, Apaydin T, Gazioglu N, Tanriover N, Oz B, Kadioglu P. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary 2018;21:335-46. [PMID: 29455389 DOI: 10.1007/s11102-018-0876-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci 2020;21:E1682. [PMID: 32121432 DOI: 10.3390/ijms21051682] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
7 Dénes J, Kasuki L, Trivellin G, Colli LM, Takiya CM, Stiles CE, Barry S, de Castro M, Gadelha MR, Korbonits M. Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS One 2015;10:e0117107. [PMID: 25658813 DOI: 10.1371/journal.pone.0117107] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
8 Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas. Cancer Lett 2015;359:299-306. [PMID: 25637790 DOI: 10.1016/j.canlet.2015.01.037] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
9 Ku CR, Lim H, Lee YJ, Kim SH, Kim D, Kim SH, Lee MK, Bang D, Lee EJ. Novel somatic variants involved in biochemical activity of pure growth hormone-secreting pituitary adenoma without GNAS variant. Sci Rep 2021;11:16530. [PMID: 34400688 DOI: 10.1038/s41598-021-95829-3] [Reference Citation Analysis]
10 Wildemberg LE, Henriques D, Elias PCL, Lima CHA, Musolino NRC, Camacho AHS, Faria O, Nazato D, Abucham J, Vilar L, Mota JI, Huayllas MKP, Chimelli L, Castro M, Kasuki L, Gadelha MR. gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Cancers (Basel) 2021;13:4857. [PMID: 34638340 DOI: 10.3390/cancers13194857] [Reference Citation Analysis]
11 Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 2020;182:583. [PMID: 32217809 DOI: 10.1530/EJE-19-0762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
12 Ibáñez-Costa A, Korbonits M. AIP and the somatostatin system in pituitary tumours. J Endocrinol 2017;235:R101-16. [PMID: 28835453 DOI: 10.1530/JOE-17-0254] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
13 Christofides EA. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence 2016;10:1217-25. [PMID: 27471378 DOI: 10.2147/PPA.S102302] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 2021:dgab726. [PMID: 34618894 DOI: 10.1210/clinem/dgab726] [Reference Citation Analysis]
15 Vieria Neto L, Wildemberg LE, Colli LM, Kasuki L, Marques NV, Moraes AB, Gasparetto EL, Takiya CM, Castro M, Gadelha MR. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS One 2013;8:e77406. [PMID: 24098585 DOI: 10.1371/journal.pone.0077406] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
16 Gillam MP, Ku CR, Lee YJ, Kim J, Kim SH, Lee SJ, Hwang B, Koo J, Kineman RD, Kiyokawa H, Lee EJ. Somatotroph-Specific Aip-Deficient Mice Display Pretumorigenic Alterations in Cell-Cycle Signaling. J Endocr Soc 2017;1:78-95. [PMID: 29264469 DOI: 10.1210/js.2016-1004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
17 Williams F, Hunter S, Bradley L, Chahal HS, Storr HL, Akker SA, Kumar AV, Orme SM, Evanson J, Abid N, Morrison PJ, Korbonits M, Atkinson AB. Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation. The Journal of Clinical Endocrinology & Metabolism 2014;99:1122-31. [DOI: 10.1210/jc.2013-2868] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
18 Marques P, Korbonits M. Genetic Aspects of Pituitary Adenomas. Endocrinol Metab Clin North Am 2017;46:335-74. [PMID: 28476226 DOI: 10.1016/j.ecl.2017.01.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
19 van Santen SS, Daly AF, Buchfelder M, Coras R, Zhao Y, Beckers A, van der Lely AJ, Hofland LJ, Balvers RK, van Koetsveld P, van den Heuvel-eibrink MM, Neggers SJCMM. Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma. AACE Clinical Case Reports 2021. [DOI: 10.1016/j.aace.2021.12.003] [Reference Citation Analysis]
20 Mooney MA, Simon ED, Little AS. Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms. Front Surg 2016;3:45. [PMID: 27517036 DOI: 10.3389/fsurg.2016.00045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 Espinosa de los Monteros AL, Carrasco CA, Albarrán AA, Gadelha M, Abreu A, Mercado M. The role of primary pharmacological therapy in acromegaly. Pituitary 2014;17 Suppl 1:S4-10. [PMID: 24166706 DOI: 10.1007/s11102-013-0530-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Barry S, Korbonits M. Update on the Genetics of Pituitary Tumors. Endocrinol Metab Clin North Am 2020;49:433-52. [PMID: 32741481 DOI: 10.1016/j.ecl.2020.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
23 Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T, Bima C, Bracaccia ME, Lugli F, Lauretti L, Anile C, Gessi M, Colosimo C, Rindi G, Pontecorvi A, Korbonits M, De Marinis L. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine 2020;67:651-8. [PMID: 31875303 DOI: 10.1007/s12020-019-02145-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Andersen M. Management of endocrine disease: GH excess: diagnosis and medical therapy. Eur J Endocrinol 2014;170:R31-41. [PMID: 24144967 DOI: 10.1530/EJE-13-0532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary 2017;20:10-21. [PMID: 28161730 DOI: 10.1007/s11102-017-0789-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
26 Yang C, Wu H, Wang J, Hu M, Xing X, Bao X, Wang R. Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review. Medicine (Baltimore) 2017;96:e8017. [PMID: 28885368 DOI: 10.1097/MD.0000000000008017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013;169:217-223. [PMID: 23749849 DOI: 10.1530/EJE-13-0349] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
28 Wildemberg LE, da Silva Camacho AH, Miranda RL, Elias PCL, de Castro Musolino NR, Nazato D, Jallad R, Huayllas MKP, Mota JIS, Almeida T, Portes E, Ribeiro-Oliveira A, Vilar L, Boguszewski CL, Winter Tavares AB, Nunes-Nogueira VS, Mazzuco TL, Rech CGSL, Marques NV, Chimelli L, Czepielewski M, Bronstein MD, Abucham J, de Castro M, Kasuki L, Gadelha M. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. J Clin Endocrinol Metab 2021;106:2047-56. [PMID: 33686418 DOI: 10.1210/clinem/dgab125] [Reference Citation Analysis]
29 Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 2017;20:109-15. [PMID: 27778296 DOI: 10.1007/s11102-016-0768-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
30 Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. Minerva Endocrinol 2019;44. [DOI: 10.23736/s0391-1977.18.02933-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
31 Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 2015;417:73-83. [PMID: 26391562 DOI: 10.1016/j.mce.2015.09.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
32 Gil J, Jordà M, Soldevila B, Puig-Domingo M. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly. Front Endocrinol (Lausanne) 2021;12:646210. [PMID: 33790868 DOI: 10.3389/fendo.2021.646210] [Reference Citation Analysis]
33 Gil J, Marques-Pamies M, Jordà M, Fajardo-Montañana C, García-Martínez A, Sampedro M, Serra G, Salinas I, Blanco A, Valassi E, Sesmilo G, Carrato C, Cámara R, Lamas C, Casano-Sancho P, Alvarez CV, Bernabéu I, Webb SM, Picó A, Marazuela M, Puig-Domingo M; on behalf REMAH investigators. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas. Clin Endocrinol (Oxf) 2021;94:811-9. [PMID: 32978826 DOI: 10.1111/cen.14339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018;70:763-835. [PMID: 30232095 DOI: 10.1124/pr.117.015388] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 23.3] [Reference Citation Analysis]
35 Liu W, Xie L, He M, Shen M, Zhu J, Yang Y, Wang M, Hu J, Ye H, Li Y, Zhao Y, Zhang Z. Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues. Int J Endocrinol 2017;2017:9606985. [PMID: 28396686 DOI: 10.1155/2017/9606985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Pichler R, Kalev O, Tomancok B, Sonnberger M, Ehrlich D, Hodolic M. Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course. Diagnostics (Basel) 2021;11:1050. [PMID: 34200337 DOI: 10.3390/diagnostics11061050] [Reference Citation Analysis]
37 Fortunati N, Guaraldi F, Zunino V, Penner F, D'Angelo V, Zenga F, Pecori Giraldi F, Catalano MG, Arvat E. Effects of environmental pollutants on signaling pathways in rat pituitary GH3 adenoma cells. Environ Res 2017;158:660-8. [PMID: 28732322 DOI: 10.1016/j.envres.2017.07.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 2016;10:227-39. [PMID: 26811671 DOI: 10.2147/DDDT.S77999] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X, Li Y, Zhang Z, Ye H, He M, Lu B, Yao Z, Lu Y, Qiao N, Ye Z, Zhang Y, Yang Y, Zhao Y, Wang Y. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 2016;58:1057-65. [PMID: 27516099 DOI: 10.1007/s00234-016-1728-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
40 Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely AJ, Neggers SJ, Lamberts SW, Pereira AM, Ferone D, Hofland LJ. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 2016;174:651-62. [PMID: 26888629 DOI: 10.1530/EJE-15-0391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
41 Marina D, Burman P, Klose M, Casar-Borota O, Luque RM, Castaño JP, Feldt-Rasmussen U. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache. Growth Horm IGF Res 2015;25:262-7. [PMID: 26188991 DOI: 10.1016/j.ghir.2015.07.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
42 Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, Herrera-Martínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol 2021. [PMID: 34601790 DOI: 10.1002/1878-0261.13107] [Reference Citation Analysis]
43 Wildemberg LE, Kasuki L, Gadelha MR. Precision medicine in the medical management of pituitary tumors. Current Opinion in Endocrine and Metabolic Research 2018;1:57-62. [DOI: 10.1016/j.coemr.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Wildemberg LE, Gadelha MR. Pasireotide for the treatment of acromegaly. Expert Opinion on Pharmacotherapy 2015;17:579-88. [DOI: 10.1517/14656566.2016.1146688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
45 Iglesias P, Rodríguez Berrocal V, Díez JJ. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine 2018;61:407-21. [DOI: 10.1007/s12020-018-1645-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
46 Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Chimelli L, Luque RM, Kasuki L, Gadelha MR. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly. J Cell Mol Med 2018;22:2110-6. [PMID: 29377493 DOI: 10.1111/jcmm.13427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
47 Kasuki L, Antunes X, Lamback EB, Gadelha MR. Acromegaly: Update on Management and Long-Term Morbidities. Endocrinol Metab Clin North Am 2020;49:475-86. [PMID: 32741483 DOI: 10.1016/j.ecl.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Alband N, Korbonits M. Familial pituitary tumors. Handb Clin Neurol 2014;124:339-60. [PMID: 25248598 DOI: 10.1016/B978-0-444-59602-4.00023-X] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
49 Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-88. [PMID: 24183675 DOI: 10.1016/j.tips.2013.10.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
50 Gadelha MR. A paradigm shift in the medical treatment of acromegaly: from a 'trial and error' to a personalized therapeutic decision-making process. Clin Endocrinol (Oxf) 2015;83:1-2. [PMID: 25880812 DOI: 10.1111/cen.12797] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
51 Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs 2014;19:79-97. [PMID: 24400774 DOI: 10.1517/14728214.2014.875529] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
52 Chiloiro S, Bima C, Tartaglione T, Giampietro A, Gessi M, Lauretti L, Anile C, Colosimo C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. J Clin Endocrinol Metab 2019;104:5478-82. [PMID: 31219586 DOI: 10.1210/jc.2019-00825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
53 Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. European Journal of Endocrinology 2016;174:241-50. [DOI: 10.1530/eje-15-0832] [Cited by in Crossref: 75] [Cited by in F6Publishing: 39] [Article Influence: 12.5] [Reference Citation Analysis]
54 Ogawa S, Matsuzaki T, Noda M. Abundant expression of the membrane-anchored protease-regulator RECK in the anterior pituitary gland and its implication in the growth hormone/insulin-like growth factor 1 axis in mice. Mol Cell Endocrinol 2020;508:110790. [PMID: 32165171 DOI: 10.1016/j.mce.2020.110790] [Reference Citation Analysis]
55 Ting Lim DS, Fleseriu M. Personalized Medical Treatment in Patients with Acromegaly: A Review. Endocr Pract 2022:S1530-891X(22)00004-0. [PMID: 35032649 DOI: 10.1016/j.eprac.2021.12.017] [Reference Citation Analysis]
56 Fernandez-Rodriguez E, Casanueva FF, Bernabeu I. Update on prognostic factors in acromegaly: Is a risk score possible? Pituitary 2015;18:431-40. [PMID: 24858722 DOI: 10.1007/s11102-014-0574-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
57 Okuma H, Bouchi R, Masuda S, Takeuchi T, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Suppression of Extrapancreatic Glucagon by Octreotide May Reduce the Fasting and Postprandial Glucose Levels in a Diabetic Patient after Total Pancreatectomy. Intern Med 2017;56:3061-6. [PMID: 28943578 DOI: 10.2169/internalmedicine.8963-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
58 Chauvet N, Romanò N, Meunier A, Galibert E, Fontanaud P, Mathieu M, Osterstock G, Osterstock P, Baccino E, Rigau V, Loiseau H, Bouillot-eimer S, Barlier A, Mollard P, Coutry N. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas. J Neuroendocrinol 2016;28. [DOI: 10.1111/jne.12352] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
59 Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Sánchez-Sánchez R, Chimelli L, Kasuki L, Luque RM, Gadelha MR. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Sci Rep 2019;9:1122. [PMID: 30718563 DOI: 10.1038/s41598-018-37692-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
60 Chang M, Yang C, Bao X, Wang R. Genetic and Epigenetic Causes of Pituitary Adenomas. Front Endocrinol (Lausanne) 2020;11:596554. [PMID: 33574795 DOI: 10.3389/fendo.2020.596554] [Reference Citation Analysis]
61 Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 2017;20:100-8. [DOI: 10.1007/s11102-017-0791-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
62 Cuevas-ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. Journal of Molecular Endocrinology 2014;52:R223-40. [DOI: 10.1530/jme-14-0011] [Cited by in Crossref: 94] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
63 Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 2016;23:R551-66. [PMID: 27697899 DOI: 10.1530/ERC-16-0151] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
64 Nista F, Corica G, Castelletti L, Khorrami K, Campana C, Cocchiara F, Zoppoli G, Prior A, Rossi DC, Zona G, Ferone D, Gatto F. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Front Endocrinol (Lausanne) 2021;12:677919. [PMID: 34025586 DOI: 10.3389/fendo.2021.677919] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Maia B, Kasuki L, Gadelha MR. Novel therapies for acromegaly. Endocr Connect 2020;9:R274-85. [PMID: 33434151 DOI: 10.1530/EC-20-0433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Gatto F, Feelders R, van der Pas R, Kros JM, Dogan F, van Koetsveld PM, van der Lelij A, Neggers SJCMM, Minuto F, de Herder W, Lamberts SWJ, Ferone D, Hofland LJ. β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly. Endocrinology 2013;154:4715-25. [DOI: 10.1210/en.2013-1672] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
67 Corica G, Ceraudo M, Campana C, Nista F, Cocchiara F, Boschetti M, Zona G, Criminelli D, Ferone D, Gatto F. Octreotide-Resistant Acromegaly: Challenges and Solutions. Ther Clin Risk Manag 2020;16:379-91. [PMID: 32440136 DOI: 10.2147/TCRM.S183360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
68 Biagetti B, Obiols G, Martinez Saez E, Cordero E, Mesa J. Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine. Endocrinol Diabetes Nutr (Engl Ed) 2018;65:130-2. [PMID: 29371000 DOI: 10.1016/j.endinu.2017.12.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Kurahashi K, Endo I, Kondo T, Morimoto K, Yoshida S, Kuroda A, Aihara KI, Matsuhisa M, Nakajima K, Mizobuchi Y, Nagahiro S, Abe M, Fukumoto S. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review. Intern Med 2017;56:2455-61. [PMID: 28824054 DOI: 10.2169/internalmedicine.8223-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Carrasco CA, Gadelha M, Manavela M, Bruno OD. Aggressive tumors and difficult choices in acromegaly. Pituitary 2014;17 Suppl 1:S24-9. [PMID: 24293348 DOI: 10.1007/s11102-013-0538-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
71 Kasuki L, Wildemberg LE, Gadelha MR. MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. European Journal of Endocrinology 2018;178:R89-R100. [DOI: 10.1530/eje-17-1006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
72 Cuny T, Chanson P. [Aggressive and resistant-to-treatment pituitary tumors]. Ann Endocrinol (Paris) 2013;74 Suppl 1:S3-12. [PMID: 24356289 DOI: 10.1016/S0003-4266(13)70016-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Reference Citation Analysis]
74 Melmed S, Kleinberg DL, Bonert V, Fleseriu M. Acromegaly: Assessing the Disorder and Navigating the Therapeutic Options for Treatment. Endocrine Practice 2016;20:7-17. [DOI: 10.4158/ep14430.ra] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
75 Xie T, Tang Y, Luo R, Zhang X, Wu S, Gu Y, Liu T, Hu F. GPR64 promotes cAMP pathway in tumor aggressiveness in sparsely granulated growth hormone cell adenomas. Endocrine 2020;68:629-39. [PMID: 32180116 DOI: 10.1007/s12020-020-02263-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
76 Tritos NA. The role of pasireotide in the treatment of acromegaly. Lancet Diabetes Endocrinol 2014;2:855-6. [PMID: 25260837 DOI: 10.1016/S2213-8587(14)70175-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 2016;19:235-47. [PMID: 26519143 DOI: 10.1007/s11102-015-0684-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
78 Marazuela M, Ramos-leví AM, Borges de Souza P, Zatelli MC. Is receptor profiling useful for predicting pituitary therapy? European Journal of Endocrinology 2018;179:D15-25. [DOI: 10.1530/eje-18-0549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Cai F, Hong Y, Xu J, Wu Q, Reis C, Yan W, Wang W, Zhang J. A Novel Mutation of Aryl Hydrocarbon Receptor Interacting Protein Gene Associated with Familial Isolated Pituitary Adenoma Mediates Tumor Invasion and Growth Hormone Hypersecretion. World Neurosurg 2019;123:e45-59. [PMID: 30447469 DOI: 10.1016/j.wneu.2018.11.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Bogusławska A, Korbonits M. Genetics of Acromegaly and Gigantism. J Clin Med 2021;10:1377. [PMID: 33805450 DOI: 10.3390/jcm10071377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Efstathiadou ZA, Bargiota A, Chrisoulidou A, Kanakis G, Papanastasiou L, Theodoropoulou A, Tigas SK, Vassiliadi DA, Alevizaki M, Tsagarakis S. Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. Pituitary 2015;18:861-7. [PMID: 26115707 DOI: 10.1007/s11102-015-0662-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]